MetaCap

Taysha Gene Therapies (TSHA) vs Windward Bio Group (WWB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Windward Bio Group is the larger company by market cap ($1.45 billion vs $1.21 billion), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

TSHA-9.27%WWB-14.79%
+7%-8%-22%
Nov 13, 20261 yearNov 20, 2026
TSHA-9.27%WWB-14.79%
+1%-7%-16%
Nov 9, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

TSHA versus WWB key metrics
MetricTSHAWWB
Share price$3.72$24.29
Market cap$1.21B$1.45B
1-day change-1.33%+1.15%
YTD return-32.36%—
1-year return-11.22%—
5-year return-70.69%—
EPS (TTM)$-0.42$-1.18
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$9.77M—
Revenue growth (YoY)+17.28%—
Net income (latest FY)$-109.00M—
Operating margin-1130.65%—
Net margin-1115.27%—
52-week high$7.30$33.99
52-week low$3.46$18.35
Distance from 52-week high-49.04%-28.55%
Analyst consensusstrong_buy—
Avg. price target upside+249.46%—
Average volume3.59M434.33K
Shares outstanding326.05M59.58M
Employees9933
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Taysha Gene Therapies

TSHA stock →

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 99 employees

About Windward Bio Group

WWB stock →

Windward Bio Group AG operates as a clinical stage biotechnology company that develops ultra-long-acting antibody medicines for patients with respiratory and dermatologic diseases. Its drug candidates WIN378, an ultra-long-acting and novel fully human monoclonal antibody, which has completed Phase I clinical study that inhibits thymic stromal lymphopoietin (TSLP); and WIN027, an ultra-long-acting bispecific antibody that is in Phase I clinical study simultaneously targets TSLP and interleukin-13 (IL-13) and two clinically validated drivers of inflammatory disease.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 33 employees

TSHA vs WWB FAQ

Which is bigger, Taysha Gene Therapies or Windward Bio Group?

Windward Bio Group (WWB) is larger, with a market capitalization of $1.45B compared with $1.21B for Taysha Gene Therapies (TSHA).

Are Taysha Gene Therapies and Windward Bio Group in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons